NEW YORK (GenomeWeb News) – Roche Diagnostics this week said that it has opened a West Coast training center in Pleasanton, Calif. The new center is housed at a facility owned by Roche Molecular Systems, and will provide customers with training on the firms molecular diagnostics and clinical chemistry/immunochemistry instruments. The firm said it plans to open a similar facility on the in New Jersey next year.
Nuclea Diagnostic Laboratories has received accreditation from the College of American Pathologists for its diagnostic lab operations at Clark University in Worcester, Mass. The firm carries out molecular pathology testing services at the lab.
Quebec-based Warnex said that it has received C$676,100 (US$639,203) from the Northern Ontario Heritage Fund to work with the Paleo-DNA Laboratory of Lakehead University to develop a forensics database. The new database will be based on mitochondrial DNA and will be the first such database in Canada.
BioDiscovery said this week that three cancer centers had renewed and/or expanded their licenses to the firm's Nexus Copy Number software. The firm said that Fox Chase Cancer Center's Keystone Program in Blood Cell Development and Cancer had renewed a multi-user license, while the City of Hope Comprehensive Cancer Center and the National Cancer Institute both renewed and expanded their licenses.
Genedata said that the Fundación Medina, based in Granada, Spain, has licensed its GeneData Screener platform, including the Condeso module for dose-response curve fitting and Kinetics Analyzer module for the capture of time series data, for data processing, management, and analysis of its natural product screening and lead evaluation series.
The Interdisciplinary Center for Biotechnology Research at the University of Florida will use GenomeQuest's platform for sequence data management in next-generation sequencing-based services, GenomeQuest said this week.
Deltagen announced yesterday that it has acquired Benten BioServices, a Pennsylvania-based contract services organization that conducts biosafety testing, raw materials testing, assay and process validation services, cell banking and characterization services, and technology platform-specific R&D support and consulting services. Deltagen issued 9,126,085 shares of its common stock, which closed at $.07 per share yesterday, to the former Benten shareholders. In addition, it said that Penn Venture Partners and Life Sciences Greenhouse of Central Pennsylvania invested $1,250,000 and $250,000, respectively, in the newly combined company.